MiMedx Group, Inc. Q2 FY2026 earnings call

Overall Quarterly Performance

• The company delivered a strong Q2 2026, with 9% sequential company-wide revenue growth. June monthly revenue reached $24 million, already putting the company within its previously stated full-year revenue guidance range even before accounting for the Sonara acquisition.
• Expense reduction initiatives were implemented, and the company returned to profitability by the end of the quarter, and expects to be profitable on a standalone organic basis in the second half of 2026.

Sonara Acquisition Strategic Rationale

• The acquisition accelerates Memetics' stated strategic plan to expand its surgical product portfolio. Sonara's product portfolio is highly complementary to Memetics' existing offerings, with minimal product, target physician, or procedure overlap and almost no expected cannibalization.
• Memetics' larger commercial organization can expand penetration of Sonara's existing products, including the opportunity to bring a BioSurge product variant into the wound care center segment, which Sonara has not meaningfully penetrated due to limited market reach.
• The acquisition adds an early-stage development pipeline (including the Ostick bone adhesion product) to Memetics' portfolio. The two companies have aligned cultures, and the Sonara team was viewed favorably by Memetics leadership.
• The transaction is immediately accretive across the income statement. Sonara already generates healthy adjusted EBITDA margins, and the combined company will deliver strong profitability post-close after realizing expected synergies.

Wound Care Business Recovery

• All current wound care growth is concentrated in HOPD wound care centers, with no sequential growth seen in other sites of service. The company holds a strong position in this growing segment, and is seeing positive recovery trends as patient volume returns to wound care centers.
• The company repurchased close to 3.5 million shares in Q2 2026 at an average price of $3.67 per share. The buyback was paused as the Sonara acquisition moved toward closing.

This transcript does not disclose full segmented financial performance with absolute revenue figures and revenue contribution percentages for all of Memetics' product segments. The only available segment-level performance data is: 1) Surgical segment: Revenue grew 15% year-over-year. 2) Wound care segment: Sequential overall volume growth was 22%, while sequential volume growth specifically in hospital outpatient department (HOPD) wound care centers reached 44%, with year-over-year volume growth achieved in this sub-segment. For the acquired Sonara business, its trailing twelve month (LTM) revenue is approximately $100 million, with gross margins over 90%. Most of Sonara's LTM revenue comes from its Celerate Rx product, with a meaningful share from its BioSurge rinse product, while the Ostick bone adhesion product remains in development.

• Full-year 2026 organic revenue is already on track to hit the prior guidance range based on June 2026 monthly revenue run rate, with the Sonara acquisition adding additional revenue. The combined company is expected to exceed $400 million in total annual revenue, with management providing this as a conservative estimate.
• The company will be profitable on a standalone organic basis in the second half of 2026, and expects the combined company post-acquisition to deliver a 20%+ adjusted EBITDA margin, a conservative target.
• For 2027, organic revenue growth is expected to return to normal rates, with organic adjusted EBITDA margin expected to reach well into the double digits. Both the wound care and surgical franchises are expected to grow next year.
• Post-acquisition, total outstanding shares will see a net increase of only ~700,000 shares: ~4.2 million new shares will be issued for the deal, offset by the 3.5 million shares repurchased in Q2.

• The wound care market is still in an early recovery phase, with ongoing market headwinds including claim processing challenges at the Medicare Administrative Contractor (MAC) level.
• CMS implementation of the Wiser wound care payment model has created a material headwind for the company in four states.
• Many existing wound care customers have exited the market, and remaining providers are facing ongoing audits and payment callbacks that create broader market challenges.
• Integration planning for the Sonara acquisition is still in very early stages, and final synergy and overlap details have not yet been finalized.

Q: What product-specific factors make the Sonara acquisition the right strategic fit, and how do synergies and product overlap look? / A: The acquisition accelerates Memetics' long-stated plan to expand its surgical portfolio, which has already delivered strong growth from prior product licensing investments. Sonara has three key products: the commercially successful, well-penetrated Celerate Rx, the commercially available BioSurge rinse, and the in-development Ostick bone adhesion product. Memetics' larger commercial reach can expand sales of all three, and there is very little overlap or expected cannibalization with Memetics' existing portfolio. The two companies also have well-aligned cultures, which was a key factor in approving the deal.

Q: Where does the expected $20 million in acquisition synergies come from, and what profitability metric does "strong profitability post-close" refer to? / A: More than half of the $20 million in total expected synergies will come from general and administrative (G&A) cost overlaps, with the remaining savings spread across other functions. Profitability is focused primarily on adjusted EBITDA initially. Sonara already has a track record of strong margin performance, so when combined with Memetics' expected organic profitability in the back half of 2026 and the realized synergies, the combined company will have a very healthy financial profile. The deal is immediately accretive across the entire income statement, which is rare for acquisitions of this size.

Q: Why was Sonara willing to sell to Memetics at this time, and how much investment is needed to capture the large $4 billion new TAM from the acquisition? / A: Memetics cannot speak for Sonara's leadership, but Sonara remains bullish on its business, has delivered consistent growth over the past year, and has a robust pipeline. Memetics' larger existing commercial presence creates immediate cross-selling opportunities across the combined portfolio. The acquired TAM is large, underpenetrated, and still developing, with significant upside for growth as adoption of these surgical products expands across subspecialties.

Q: What is the current trend for Memetics' wound care business, specifically for the MAX product line? / A: Memetics cannot share overall market data as it does not have access to reliable industry wide data, but can speak to its own performance. As expected, patient volume has been returning to wound care centers, and Memetics' strong position in that segment has driven the positive sequential growth trends the company reported. The market is still in early recovery, with ongoing headwinds from claim processing issues, the CMS Wiser model rollout, and industry-wide audit and callback challenges, but Memetics is seeing strong progress specifically in the HOPD wound care center segment.